metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	pembrolizumab plus SoC
	KEYNOTE-361 (PC vs C), 2021 Annals of Oncology Lancet Oncol 2021 May 26;S1470-2045(21)00152-2. NCT02853305	RCT	mUC - L1 - all population	pembrolizumab plus chemotherapy	chemotherapy alone (cisplatine or carbo plus gemcitabine)	patients with histologically or cytologically confirmed unresectable/metastatic urothelial carcinoma, who received no prior systemic chemotherapy for advanced urothelial cancer	351 / 352	some concern	inconclusive	inconclusive 14 % decrease in deaths (OS) (PE) suggested 22 % decrease in progression or deaths (PFS) (PE)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-361 (P vs C), 2021 Annals of Oncology Lancet Oncol 2021 May 26;S1470-2045(21)00152-2. NCT02853305	RCT	mUC - L1 - all population	pembrolizumab	chemotherapy alone (cisplatine or carbo plus gemcitabine)	patients with histologically or cytologically confirmed unresectable/metastatic urothelial carcinoma, who received no prior systemic chemotherapy for advanced urothelial cancer	307 / 352	some concern	inconclusive	statistically significant 35 % increase in progression or deaths (PFS) statistically significant 47 % decrease in objective responses (ORR)